| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1216471 | Journal of Chromatography B | 2013 | 6 Pages |
•Disulfiram has therapeutic application in cancer.•Solid phase extraction was utilized in the separation of disulfiram.•Determination of disulfiram was firstly conducted by UPLC–ESI-MS/MS method.•The method possesses a LLOQ of 0.6 ng/mL, much lower than previous methods.•The method with stabilizing agent added showed better reproducibility.
Disulfiram (DSF) has been used to treat alcoholism for many years and it has been suggested to play a key role in combatting many kinds of tumors. However, disulfiram has complex pharmacokinetics and is rapidly eliminated which limits its use as a tumor treatment. Therefore, a rapid and sensitive analytical method based on ultra performance liquid chromatography coupled to electrospray ionization-tandem mass spectrometry (UPLC–ESI-MS/MS) was developed and validated for the determination of disulfiram in rat plasma. Blood samples were pre-stabilized with a stabilizing agent and then plasma was obtained and subjected to solid phase extraction (SPE), and chromatographed on a Phenomenex Kinetex® XB C18 column with gradient elution using a mobile phase consisting of acetonitrile–water (containing 0.1% formic acid and 1 mM ammonium acetate) at a flow rate of 0.2 mL/min for 3 min. Multiple reactions monitoring in positive mode was carried out with disulfiram at 296.95/115.94 and diphenhydramine (internal standard, IS) at 256.14/167.02 over a linear range from 0.6 to 1200 ng/mL. The extraction recovery of disulfiram for different concentrations ranged from 75.7% to 78.3%. The intra- and inter-day precision was less than 8.93% and 12.39%, respectively, and the accuracy was within ±7.75%. The validated method was successfully applied to a pharmacokinetic study of disulfiram in rat plasma after oral administration of a dose of 180 mg/kg.
